For COVID-19 Convalescent Plasma Program Requirements Click Here!
News & Views
Newsletters
Donate
Contact
Search
Close
News & Views
Newsletters
Donate
Contact
Search
Close
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Menu
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Menu
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Donate
5323 S. McColl Rd., Edinburg, TX 78539
dhrresearch@dhr-rgv.com
(956) 362-2390
Trial Category: Liver Disease
Results
A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non alcoholic Fatty Liver Disease (NAFLD) (MAESTRO NAFLD-1)
View Details →
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH)
View Details →
Cohort Analysis of Non-alcoholic Fatty Liver Disease and Associated Diagnostic Performance of FibroScan
View Details →
A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis
View Details →
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF AKR-001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
View Details →
A Study of AKR-001 in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
View Details →
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)
View Details →
A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
View Details →
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
View Details →
A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
View Details →
